Finance
Study Budgets — filter by USD & rolling period
Studies matching
132
Total budget (USD)
$ 871,058,901
Average per study
$ 6,598,931
Filters
≥ $250,000 ·
Local ·
Last 1y ·
Approved
Matching studies
| # | UNCST Ref | PI | Title | Approved | Turnaround (days) | Total (USD) |
|---|---|---|---|---|---|---|
| 1 | HS4777ES |
Rita Nassanga ritanassanga@gmail.com
|
USE OF BRAIN MAGNETIC RESONANCE IMAGING FOR DEMENTIA DIAGNOSIS IN UGANDA | 2025-07-22 | 256 | $ 114,500,600 |
| 2 | SS3959ES |
Eddy Walakira ewalakira@gmail.com
|
SKILLING IN AGRIPRENEURSHIP FOR INCREASED YOUTH EMPLOYMENT (SAY) PROJECT | 2025-08-07 | 65 | $ 90,000,000 |
| 3 | SS4063ES |
PETER KADDU kaddupeter2@gmail.com
|
Human Resource Planning Practices and Perceived Health Service Delivery in Uganda; a case study of selected District in Central Uganda. | 2025-08-07 | 28 | $ 74,790,000 |
| 4 | SS4234ES |
Tenywa Kawanguzi derick.tenywa@gu.ac.ug
|
DETERMINANTS OF SMALLHOLDER FARMERS� VULNERABILITY: A CONFLUENCE OF CLIMATE CHANGE AND OTHER CONTEXTUAL FACTORS IN ACHOLI SUB-REGION, NORTHERN UGANDA | 2026-02-12 | 149 | $ 70,100,000 |
| 5 | HS6455ES |
Alen Musisi alenmusisi2012@gmail.com
|
Exploring the Frequency and Perceived Scope of Radiation Protection Information in Continuous Medical Education Among Radiation Workers in Uganda | 2025-10-21 | 29 | $ 40,915,000 |
| 6 | HS7189ES |
James Tumwine jameskashugyera@gmail.com
|
MICROSPORIDIOSIS AMONG CHILDREN AND ADULTS WITH PERSISTENT DIARRHEA AT KABALE REGIONAL AND MULAGO NATIONAL REFERRAL HOSPITALS: ASSOCIATED FACTORS AND GENOMIC SEQUENCING | 2026-04-29 | 61 | $ 30,096,000 |
| 7 | SS5070ES |
John Mary Kanyamurwa jmkanyamurwa@kyu.ac.ug
|
Climate Change Threats to Livelihood Resilience and Adaptive Governance in Uganda's Bulambuli District | 2026-04-20 | 40 | $ 28,690,700 |
| 8 | SIR633ES |
Lynn Tar Janet Gutu lynntar2@gmail.com
|
An AI system to assist the visually and auditory impaired by generating speech from text queries and vice versa for Uganda�s local languages | 2026-04-02 | 19 | $ 25,910,000 |
| 9 | SS4727ES |
Deborah Kirabo denorah5@gmail.com
|
Documentation of RAHU Peer Education Model | 2026-02-18 | 9 | $ 25,213,599 |
| 10 | SS4330ES |
Daudi Hasahya-Mulongo dhmulongo@yahoo.com
|
Predictors of Retirement Readiness, and Planned Coping Strategies among Headteachers of Public Secondary Schools in Uganda | 2025-09-17 | 77 | $ 23,522,000 |
| 11 | HS6938ES |
Byaruhanga RichardSserioza bsrkasoloser@gmail.com
|
Effects, Risk Factors, and Treatment Outcomes Among Patients with Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Southwestern Uganda | 2026-02-20 | 55 | $ 23,342,000 |
| 12 | SS3574ES |
Victoria Nzarubara vikki.nzaru@gmail.com
|
Digital Transformation, Quality of Work Life, Subjective Well-Being and Coping strategies in the Uganda Police Force | 2025-09-24 | 257 | $ 21,873,600 |
| 13 | SS4926ES |
MAURICE ALEX MUHWEZI MURARI maurice.muhwezimurari@gmail.com
|
Parenting Styles and Psychological Well-Being among Adolescents in Secondary Schools in Uganda: A Case of Kabale District in Western Uganda | 2026-03-30 | 29 | $ 21,818,534 |
| 14 | SS4070ES |
Confidence Nkurunungi Asiimwe asiimweco@gmail.com
|
Parent Alcohol Use, Harsh Parenting,Adolescent Alcohol Use and Mental Illness among Adolescents in Kabale District, Southwestern Uganda | 2025-07-22 | 25 | $ 21,520,000 |
| 15 | SS3479ES |
ESTHER NANSAMBA nansamba.esther@yahoo.com
|
SUCCESSION PLANNING PRACTICES, ORGANIZATIONAL CULTURE AND SURVIVABILITY OF HOTELS IN WESTERN UGANDA | 2025-08-08 | 39 | $ 21,370,000 |
| 16 | SS4680ES |
Precious Natureeba natureebaprecious@gmail.com
|
Perceived Organizational Justice, Support, Commitment and Citizenship Behavior of teachers in Government Grant Aided Secondary Schools of Greater Bushenyi Sub-Region | 2026-01-30 | 105 | $ 18,900,000 |
| 17 | SS4974ES |
ISMAEL BARUGAHARE ismael4responses@gmail.com
|
SUSTAINABLE SUPPLY CHAIN MANAGEMENT PRACTICES, GOVERNANCE MECHANISMS AND SUSTAINABILITY PERFORMANCE OF NATIONAL OIL AND GAS SECTOR PROJECTS IN UGANDA | 2026-04-30 | 59 | $ 17,000,000 |
| 18 | NS1001ES |
BRIGHT NDAHIRO ndahiro.bright@gmail.com
|
ECOLOGICAL RISK ASSESSMENT OF HEAVY METALS AND POTENTIAL USE OF SELECTED MACROPHYTES IN PHYTOREMEDIATION AND MANAGEMENT OF LAKE GEORGE, UGANDA | 2025-08-26 | 34 | $ 15,200,000 |
| 19 | SS5006ES |
Jazzilah Tumusiime jazzilah.tumusiime@studmc.kiu.ac.ug
|
SCHOOL READINESS AND IMPLEMENTATION OF COMPETENCE-BASED CURRICULUM IN PUBLIC SECONDARY SCHOOLS IN MASINDI DISTRICT, UGANDA | 2026-03-12 | 21 | $ 13,700,000 |
| 20 | SS3883ES |
Oyo Charles charlesoyo310@gmail.com
|
Governing Board Functionality in Catholic Institutions in Uganda: Critical Refelection on Education and Health Institutions | 2025-07-10 | 59 | $ 12,900,000 |
| 21 | SS5269ES |
AIDAHKIBEDI NAMBUSI aidah.nambusi@studmc.kiu.ac.ug
|
TUTOR-TEACHER SUPPORT AND PUPILS� ACHIVEMENT IN LITERACY AND NUMERACY AMONG PUBLIC BOARDING PRIMARY SCHOOLS IN GREATER MUKONO, UGANDA | 2026-05-14 | 115 | $ 12,500,000 |
| 22 | HS6666ES |
Flavia Matovu fmatovu@musph.ac.ug
|
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women | 2025-10-16 | 1 | $ 11,518,227 |
| 23 | SS4701ES |
Nicholas Mutegyeki nicholas.mutegyeki.15003@studmc.kiu.ac.ug
|
EXAMINATION OF CORPORATE GOVERNANCE IN MILITARY ENTERPRISES IN UGANDA | 2026-01-30 | 51 | $ 11,500,000 |
| 24 | NS993ES |
Emma Wamono wamonoe3@gmail.com
|
Impact of anthropogenic stressors on ecosystem health and potential in-stream restoration measures of river Manafwa catchment in eastern Uganda | 2025-12-05 | 144 | $ 8,900,000 |
| 25 | SS5180ES |
BUKIRWA N GERMINA RESTY germina.bukirwa@studmc.kiu.ac.ug
|
Corporate Culture and Organisational Sustainability in the Hotel Industry, Kampala Uganda | 2026-05-20 | 31 | $ 8,750,000 |
| 26 | SS4884ES |
Sempebwa Brian br.ssempebwa@yahoo.com
|
Corporate Governance Practices and Financial Sustainability of SACCOS in Uganda acase of Greater Bushenyi | 2026-03-26 | 19 | $ 6,400,000 |
| 27 | HS7783ES |
Fatumo Segun Adeyemi Segun.Fatumo@mrcuganda.org
|
Uncovering Molecular Determinants of Complex Diseases in Africa | 2026-06-25 | 28 | $ 6,171,112 |
| 28 | A705ES |
Irene Birabwa birabwa1irene@gmail.com
|
HOUSEHOLD PRODUCTION AND CONSUMPTION OF IRON RICH BEANS AND THE ASSOCIATED FACTORS IN KAMULI DISTRICT, EASTERN UGANDA | 2026-02-10 | 19 | $ 4,500,000 |
| 29 | HS7679ES |
Sheila Bamweyana sbamweyana@mujhu.org
|
HPTN 104: A multisite, open-label, randomized crossover study comparing adherence to a single daily dual prevention pill (DPP) versus FTC/TDF and Combined Oral Contraception separate pill dosing (2PR), given for pre-exposure prophylaxis and pregnancy prevention in women. | 2026-06-12 | 30 | $ 4,406,049 |
| 30 | SS4111ES |
SARAH NAKIYINGI sarah.nakiyingi@stud.kiu.ac.ug
|
DETERMINANTS OF STUDENTS TRANSFER IN PRIVATE UNIVERSITIES IN KAMPALA - UGANDA | 2025-10-15 | 103 | $ 4,110,000 |
| 31 | SS4556ES |
Brenda Amaido amaidojbrenda@gmail.com
|
Peace in Pieces: Histories of Conflict, Peacebuilding and Women's Agency in Teso Sub Region | 2025-12-18 | 55 | $ 3,480,000 |
| 32 | HS6715ES |
Milton Musaba miltonmusaba@gmail.com
|
High-Performance, Multivariate, Accessible Tools for Early HMB Identification and Iron Deficiency Risk Prediction (VITAL-HMB) | 2025-12-08 | 35 | $ 3,245,114 |
| 33 | HS6995ES |
Simon Peter Kibira pskibira@musph.ac.ug
|
Evaluation of feasibility, acceptability and cost of implementing a Multiple First-line Therapies strategy for treatment of uncomplicated malaria in Uganda | 2026-02-20 | 10 | $ 2,771,755 |
| 34 | HS7131ES |
Ronald Moses Galiwango rmgaliwango@rhsp.org
|
Causality of Post-TB Lung Disease: Population-Level evidence from Rural Uganda. | 2026-03-03 | 12 | $ 2,732,237 |
| 35 | HS6341ES |
Andrew Mujugira amujugira@idi.co.ug
|
Integrating HIV prevention with TB household contact evaluation in Uganda (TB PrEP) | 2025-09-17 | 92 | $ 2,674,922 |
| 36 | HS5162ES |
Tarekegn Abeku t.abeku@malariaconsortium.org
|
improving early warning and control of mosquito-borne disease outbreaks caused by extreme weather in Uganda | 2025-07-04 | 116 | $ 2,250,804 |
| 37 | HS5711ES |
David Meya david.meya@gmail.com
|
A Phase 2 Novel Antimicrobial Combination Therapy to Treat Tuberculous Meningitis | 2025-07-18 | 113 | $ 2,100,175 |
| 38 | HS6975ES |
Pauline Amuge paulacallista@gmail.com
|
Bedaquiline Roll-out Evidence in Contacts and People Living with HIV to prevent TB (BREACH-TB) | 2026-02-05 | 28 | $ 2,005,165 |
| 39 | HS7367ES |
Andrew Walakira adwalakira@gmail.com
|
Combating Antimalarial Resistance: An AI-Driven Approach to Identify andPrioritize Key Parasite Mutations | 2026-06-25 | 72 | $ 1,911,000 |
| 40 | HS6461ES |
MARIA NAMULWANA Maria.NAMULWANA@epicentre.msf.org
|
Evaluating the durability of the immune response to fractional and full dose Yellow Fever vaccination (YEFE/NIFTY Extension Study ) | 2025-09-26 | 25 | $ 1,697,762 |
| 41 | SS5344ES |
Rhona Mijumbi info@acres.or.ug
|
Learning together to advance Evidence and Equity in Policymaking to achieve the SDGs in Africa (Africa LEEPS) | 2026-06-11 | 20 | $ 1,623,964 |
| 42 | HS6483ES |
Marvious Kiwanuka kiwanukamarvious@gmail.com
|
Surveillance of human and vector behaviors to understand malaria transmission at sentinel sites in Uganda | 2025-09-30 | 25 | $ 1,459,570 |
| 43 | HS6117ES |
Esther Cathlyn Atukunda eatukunda@must.ac.ug
|
Evaluating Healthy Families PrEP: an intervention to promote PrEP use during periconception, pregnancy and postpartum periods for women in rural Uganda | 2025-07-09 | 37 | $ 1,453,000 |
| 44 | HS6882ES |
AGNES NAGGIRINYA anaggirinya@idi.co.ug
|
Evaluating the impact on 90-day survival of post-discharge follow-up strategies delivered to adult patients hospitalized with sepsis across a research network in sub-Saharan Africa [Call for Life � Sepsis (C4L-Sepsis)] | 2026-01-30 | 25 | $ 1,412,617 |
| 45 | HS7165ES |
Adoke Yeka yadoke@yahoo.com
|
STOP-AMDR: Molecular surveillance for operationally relevant genetic polymorphisms of P. falciparum in Uganda | 2026-03-12 | 15 | $ 1,388,302 |
| 46 | HS2515ES |
Adeodata Rukyalekere akekitiinwa@baylor-uganda.org
|
Long-Acting Treatment in Adolescents (LATA); A randomized open-label 2-arm 96-week trial in virologically suppressed HIV-1-positive adolescents aged 12-19 years of age in Sub-Saharan Africa version 1.0 dated 01 December 2021. | 2026-01-27 | 1,194 | $ 1,285,000 |
| 47 | HS5944ES |
Catriona Waitt cwaitt@liverpool.ac.uk
|
Acceptability and feasibility of long-acting injectable antiretroviral therapy (LAI-ART) as a bridging strategy for postpartum mothers living with HIV in South Africa and Uganda | 2025-09-17 | 142 | $ 1,245,000 |
| 48 | HS5982ES |
Catriona Waitt cwaitt@liverpool.ac.uk
|
Drug Optimisation for LMICs in Pregnant HIV mothers and their INfants: temporary switch to CAB/RPV long acting injections in postpartum period | 2025-09-17 | 138 | $ 1,215,000 |
| 49 | HS7025ES |
Ronald Moses Galiwango rmgaliwango@rhsp.org
|
Impact of pregnancy on HIV reservoir activity, and associated immune dynamics, inducibility, and clonality | 2026-02-12 | 16 | $ 1,155,613 |
| 50 | HS7337ES |
Ponsiano Ocama ponsiano.ocama@gmail.com
|
Hepatitis B and HIV Cure Consortium (BICC): A Multi-Country Prospective Observational Cohort of People with HIV and Hepatitis B (PWHHB) and People with HBV (PWHB) | 2026-04-10 | 18 | $ 1,151,089 |
| 51 | HS7432ES |
Joseph Ngonzi jngonzi@yahoo.com
|
AI-driven placental imaging tool to reduce adverse pregnancy outcomes through prediction of neonatal sepsis risk: Feasibility of clinical use | 2026-05-11 | 33 | $ 1,124,030 |
| 52 | HS6141ES |
Ponsiano Ocama ponsiano.ocama@gmail.com
|
Leveraging HIV care infrastructure for implementation of context-adapted liver cancer comprehensive control strategies in Uganda: The LC3 Study | 2025-07-22 | 22 | $ 1,088,127 |
| 53 | NS1117ES |
Dennis Muhanguzi luckydenno@covab.mak.ac.ug
|
Resilience Enhancement for Ticks and Tick-borne Diseases in Uganda [ResTick-U] | 2026-01-30 | 35 | $ 1,054,477 |
| 54 | HS6600ES |
Noeline Nakasujja drnoeline@yahoo.com
|
Vitamin D and Gut Microbiota and Dementia rick in older adults with chronic HIV infection and demographically matched community controls. Adverse Synergy of Gut Dysbiosis and Vitamin D Deficiency in Alzheimer�s Disease and Related Dementia among Community Controls and Older Adults with Chronic HIV-infection | 2025-10-17 | 16 | $ 1,053,080 |
| 55 | HS5835ES |
FREDDIE SSENGOOBA sengooba@musph.ac.ug
|
Exploring the Future of First Referral Hospitals in sub-Saharan Africa as part of Integrated Primary Care Systems: Service delivery, Workforce dynamics and Technology integration (AFRHiCARE). | 2025-07-10 | 34 | $ 1,016,500 |
| 56 | HS6565ES |
Eugene Ruzagira Eugene.Ruzagira@mrcuganda.org
|
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women | 2025-11-21 | 9 | $ 1,000,000 |
| 57 | HS7136ES |
Denis Tindyebwa dtindyebwa@anecca.org
|
Impact of nurturing care interventions on neonatal and child health outcomes in Eastern Uganda: A population-based mother-baby cohort | 2026-04-10 | 42 | $ 976,000 |
| 58 | HS6973ES |
Kamya Moses regulatory1@idrc-uganda.org
|
Triaging dolutegravir resistance via a point-of-care urine tenofovir assay (Tri-POC) | 2026-02-05 | 28 | $ 975,294 |
| 59 | HS6530ES |
Bruce Kirenga brucekirenga@yahoo.co.uk
|
Safety, preliminary efficacy, and Pharmacokinetics of Herbal/Natural/ Traditional therapeutic products for the management of Diabetes Mellitus in Uganda. | 2025-12-01 | 17 | $ 922,397 |
| 60 | HS7237ES |
Adoke Yeka yadoke@yahoo.com
|
A Phase 2A study to evaluate the safety, tolerability and pharmacokinetics of a novel antimalarial pyrrolidinamide at different doses and dose durations, in adult patients with uncomplicated P. falciparum malaria | 2026-03-19 | 13 | $ 920,000 |
| 61 | HS7398ES |
William Worodria worodria@yahoo.com
|
Program for Rifampicin-Resistant Disease with Stratified Medicine for TB� (PRISM-TB) | 2026-04-10 | 9 | $ 909,234 |
| 62 | HS6545ES |
William Worodria worodria@yahoo.com
|
Candidate Clinical Correlate as Prognostic Outcome for TB (C3PO) Study | 2025-11-21 | 61 | $ 908,294 |
| 63 | HS6327ES |
Adoke Yeka yadoke@yahoo.com
|
Randomised controlled trial to assess the efficacy of artemisinin combination therapies in a setting of emerging artemisinin resistance in Uganda. | 2025-09-09 | 49 | $ 869,597 |
| 64 | SS5421ES |
Soofia Mahmood soofia@raisingthevillage.org
|
DATA-DRIVEN TARGETING AND ADAPTATIONS FOR SCALING ULTRA POVERTY GRADUATION (UPG) IN MID WEST AND SOUTH WESTERN UGANDA | 2026-06-12 | 23 | $ 867,161 |
| 65 | HS6040ES |
Laura Nsangi jlaura88800@gmail.com
|
ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse | 2025-07-04 | 36 | $ 833,797 |
| 66 | NS1199ES |
Maria Nantongo denningyoung@gmail.com
|
Scaling Inclusive Climate Change Policy Reforms for Low carbon Transition in Uganda | 2026-03-12 | 2 | $ 806,142 |
| 67 | SS4216ES |
Viola Nyakato vnyakato@must.ac.ug
|
Caregiver-Adolescent Sexuality Communication among Refugee and Host Communities in Southwestern and Northern Uganda (CONNECT) | 2025-09-12 | 31 | $ 780,023 |
| 68 | HS5900ES |
Francis Kiweewa fkiweewa@gmail.com
|
Longitudinal observation of cardiovascular diseases among people living with HIV in Lango Sub-region, Northern-Uganda. | 2025-07-04 | 78 | $ 739,136 |
| 69 | SS5114ES |
Mark Jordans mark.jordans@warchild.nl
|
CORE: A cluster Randomised Control Trial to test the effectiveness of a teacher wellbeing intervention. | 2026-04-29 | 20 | $ 734,300 |
| 70 | HS7355ES |
Waiswa Peter pwaiswa@musph.ac.ug
|
An effectiveness-implementation trial of a peer mentorship intervention to help women navigate barriers to contraceptive use in rural Uganda | 2026-04-02 | 8 | $ 723,300 |
| 71 | HS6765ES |
Denis Nansera dnansera@gmail.com
|
The Youth TB Sentinel Research Network ("Youth TB-SRN") Study | 2025-12-18 | 35 | $ 695,065 |
| 72 | SS5142ES |
Florence Kyoheirwe flora.muhanguzi@gmail.com
|
Climate Resilience Solutions in the West Nile Region of Uganda (CARIS) | 2026-05-28 | 32 | $ 691,635 |
| 73 | SS4713ES |
Samantha Winter scw2154@columbia.edu
|
Investigating direct and indirect pathways between climate and mental health and wellbeing and development and testing of localized, impact-based early warning systems for climate vulnerable communities in Uganda, Tanzania, and Kenya | 2026-02-02 | 450 | $ 641,374 |
| 74 | HS6540ES |
Jackson Mukonzo mukojack@yahoo.co.uk
|
Safety of COVIDEX� Therapy in adults: in Uganda: A randomized controlled open- label phase 1 clinical trial. | 2025-11-21 | 60 | $ 631,579 |
| 75 | HS7072ES |
Maxson Anyolitho maxanyoli@yahoo.com
|
Implementation of an Integrated Care Model for Patients with Multiple Cardiometabolic and Mental Health Conditions in sub-Saharan Africa (M-Care) | 2026-02-10 | 9 | $ 603,675 |
| 76 | SS5074ES |
Vesall Nourani vesall.nourani@gmail.com
|
Towards a Culture of Learning at Scale through Teacher Professional Development | 2026-03-26 | 128 | $ 581,705 |
| 77 | SS4106ES |
Jackson Efitre jefitre@gmail.com
|
Scaling up fish processing technologies, marketing and women empowerment for improved incomes and livelihoods of fishing communities in Uganda (NutriFishPLUS) | 2025-08-07 | 34 | $ 563,386 |
| 78 | HS7580ES |
Winnie Muyindike wmuyindike@gmail.com
|
Exploring low-level HIV viremia among individuals on dolutegravir in sub-Saharan Africa (Low-V Africa Study). | 2026-04-30 | 41 | $ 552,715 |
| 79 | HS7291ES |
Richard Idro ridro1@gmail.com
|
Dihydroartemisinin-piperaquine for the post-discharge management of children with severe acute malnutrition in Malawi and Uganda; A multicentre, parallel-group, two-arm, randomised, double-blind superiority trial [Short Title: Post-discharge Malaria Chemoprevention - SAM (PDMC-SAM)] | 2026-04-10 | 24 | $ 519,275 |
| 80 | SS5072ES |
Joseph Babigumira babijo@ghe-insights.com
|
Behavioral Research for Informed Government Decision-Making Using Evidence (BRIDGE Trial) | 2026-04-30 | 21 | $ 507,684 |
| 81 | HS6270ES |
Elias Kumbakumba kumba2kumba@gmail.com
|
Consortium to Reduce Infant Mortality in Uganda (CONRIM-U) | 2025-07-18 | 26 | $ 493,516 |
| 82 | HS4371ES |
Godfrey Zari Rukundo grukundo@must.ac.ug
|
WHO LIVE LIFE guide with DHMT as Champions for Suicide Prevention across the lifespan in rural Uganda (WLLDC-SP) | 2025-10-17 | 355 | $ 479,245 |
| 83 | NS1012ES |
Casim Tolo tolocas@must.ac.ug
|
Action Towards Reducing Aquatic snail-borne Parasitic Diseases phase II | 2026-02-12 | 167 | $ 475,772 |
| 84 | A760ES |
John Ainembabazi j.ainembabazi@afdb.org
|
Reducing Food Loss and Waste of Fruits and Vegetables in Uganda�s Food Markets | 2026-05-28 | 21 | $ 469,979 |
| 85 | SS4343ES |
Rhona Mijumbi info@acres.or.ug
|
Digital Evidence Synthesis Tool Innovation Yielding Improvements in Climate and Health | 2025-09-26 | 28 | $ 469,820 |
| 86 | SS5248ES |
Tomos Proffitt tsproffitt@ualg.pt
|
Western Rift Archaeology and Palaeoenvironment Project (WRAP) | 2026-05-14 | 29 | $ 465,674 |
| 87 | HS7089ES |
Stephen Asiimwe sasiimwe@must.ac.ug
|
The PULM Uganda Study (Predicting Lung Health Mechanisms in Uganda) | 2026-03-03 | 20 | $ 456,176 |
| 88 | HS6218ES |
Isaac Ssewanyana sewyisaac@yahoo.co.uk
|
Use of Remnant Clinical Samples from Health Facilities for Micronutrient Surveillance in Uganda | 2025-07-07 | 12 | $ 455,733 |
| 89 | HS6333ES |
Betty Mwesigwa bmwesigwa@muwrp.org
|
CASCADE C-3001-A: Comparison of Clinic-based versus Clinic- plus Community Outreach-based Strategy to Increase Uptake of Cervical Cancer Screening via HPV Self-Collection among Women Living with HIV: a Cluster Randomized Trial. | 2025-09-03 | 36 | $ 449,430 |
| 90 | HS6925ES |
Henry Mugerwa hmugerwa@jcrc.org.ug
|
A Phase I/II clinical study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ITU512 in healthy participants and patients with sickle cell disease | 2026-05-22 | 154 | $ 443,000 |
| 91 | HS6616ES |
Noah Kiwanuka nkiwanuka@gmail.com
|
ASSESSING THE MYCOBACTERIUM TUBERCULOSIS CARRIAGE STATE | 2025-11-07 | 24 | $ 439,252 |
| 92 | HS6555ES |
ERIC WOBUDEYA ewobudeya@gmail.com
|
Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV | 2025-11-04 | 34 | $ 437,655 |
| 93 | SS4270ES |
Jennifer Davis jennadavis@stanford.edu
|
The health and well-being benefits of transitioning to piped water service: A prospective study in rural Uganda | 2025-08-19 | 7 | $ 421,512 |
| 94 | HS7242ES |
Nathan Kenya-Mugisha kenya@walimu.org
|
Smart discharges to improve post-discharge health outcomes in newborns with suspected sepsis | 2026-03-24 | 14 | $ 416,975 |
| 95 | HS6741ES |
Rosalind Parkes-Ratanshi rp549@medschl.cam.ac.uk
|
CARBON EMISSION ASSESSMENT OF ANTIRETROVIRAL THERAPY DELIVERY USING MEDICAL DRONES VERSUS STANDARD DELIVERY METHODS IN KALANGALA DISTRICT: A SUB STUDY NESTED WITHIN THE DRONES STUDY | 2026-01-30 | 78 | $ 413,412 |
| 96 | SS4668ES |
Mary Namubiru mary.namubiru@brac.net
|
PLAY 2.0 � Strengthening High Quality ECD Program through Assessment | 2026-02-05 | 15 | $ 403,644 |
| 97 | HS6607ES |
Victor Musiime vmusiime@jcrc.org.ug
|
Enhancing Novel Research for Inflammation and Cognitive Health among Adolescents and Young Adults Living with Perinatally Acquired HIV and Adversity (ENRICH+) | 2025-10-29 | 15 | $ 379,485 |
| 98 | HS6294ES |
Abel Kakuru abelkakuru@gmail.com
|
Dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone for the prevention of febrile illnesses in children with sickle cell anemia: a double-blind randomized controlled trial | 2025-10-29 | 104 | $ 379,175 |
| 99 | HS6744ES |
JOSELYN RWEBEMBERA joselynr36@gmail.com
|
A Non-Inferiority Trial of Stopping Penicillin in Early Rheumatic Heart Disease: GOAL-Stop | 2025-12-18 | 42 | $ 378,595 |
| 100 | SS4473ES |
Yueh-ya Hsu yuehya.hsu@gmail.com
|
The Impact of Microcredit for Refugees and Host Communities | 2025-10-17 | 11 | $ 378,000 |
| 101 | HS7849ES |
Pauline Byakika-Kibwika pbyakika@gmail.com
|
Platform Adaptive Randomised Trial for NEw and Repurposed Filovirus treatmentS | 2026-06-08 | 1 | $ 371,548 |
| 102 | HS6712ES |
Sarah Wilker sarah.wilker@uni-bielefeld.de
|
One size fits all? Towards individual prediction of treatment success for posttraumatic stress disorder in post-conflict settings (TRAUMA-FIT) | 2025-11-26 | 27 | $ 370,257 |
| 103 | NS1176ES |
Anthony Nsubuga ansubuga2@gmail.com
|
The consequences of biodiversity loss and land use change on infectious disease emergence | 2026-04-10 | 24 | $ 355,000 |
| 104 | A693ES |
Godfrey Kubiriza godfrey.kubiriza@mak.ac.ug
|
ECO-INNOVATIVE TECHNOLOGIES FOR IMPROVED NUTRITION, SUSTAINABLE PRODUCTION AND MARKETING OF AGROECOLOGICAL FOOD PRODUCTS IN AFRICA(INNOECOFOOD) | 2026-02-05 | 49 | $ 354,749 |
| 105 | HS6556ES |
Jane Kabami jkabami@idrc-uganda.org
|
Peerled Dynamic Choice HIV Prevention for Women. The Peer-led DCP Study | 2025-10-29 | 36 | $ 352,208 |
| 106 | A670ES |
Ibrahim Wanyama i.wanyama@cgiar.org
|
CIRcularity of Nutrients in AgroecoSystems and co-benefits on animal and human health (CIRNA) | 2026-02-20 | 16 | $ 352,202 |
| 107 | HS6352ES |
Allan Kalungi Allan.Kalungi@mrcuganda.org
|
Harnessing DNA Methylation Variation Between Populations to Understand Disease Discordance Across Ancestries | 2025-09-17 | 43 | $ 345,520 |
| 108 | HS6251ES |
Hakim Kalungi Hakim.Kalungi@rescue.org
|
Process evaluation of the She Cares Program model in Uganda. | 2025-10-17 | 102 | $ 336,252 |
| 109 | HS6260ES |
Esther Cathlyn Atukunda eatukunda@must.ac.ug
|
Exploring the implementation of new PrEP methods during periconception, throughout pregnancy, and after childbirth | 2025-08-18 | 39 | $ 329,000 |
| 110 | HS6344ES |
Adoke Yeka yadoke@yahoo.com
|
An open-label, randomised, controlled, non-inferiority trial to compare the efficacy, safety and tolerability of a fixed dose Triple Artemisinin-based Combination Therapy (TACT) artemether-lumefantrine-amodiaquine versus first-line Artemisinin-based Combination Therapies (ACTs) for the treatment of uncomplicated Plasmodium falciparum malaria | 2025-09-26 | 45 | $ 328,620 |
| 111 | HS7101ES |
David Ogwang dmogwang2@gmail.com
|
Saliva and Plasma EBV to Enhance Diagnosis (SPEED) | 2026-03-19 | 33 | $ 324,543 |
| 112 | HS6821ES |
alfred andama andama.alf@gmail.com
|
Evaluation of a novel molecular platform for MTB detection using contrived oral swab samples | 2026-04-10 | 79 | $ 316,265 |
| 113 | HS6410ES |
Barnabas Bakamutumaho bbarnabas2001@yahoo.com
|
Countrywide Enhancement of Sentinel Congenital Rubella Surveillance and Intensified Case Identification for Burden Monitoring Following Measles-Rubella Vaccine Introduction in Uganda and Neighboring Countries | 2025-08-26 | 76 | $ 310,890 |
| 114 | SS5125ES |
David Mafigiri dmk28@case.edu
|
Testing on the frontline: empowering health engagement through �rational use� of diagnostics for infectious and non-communicable disease (TIYENI Dx) | 2026-04-20 | 12 | $ 300,000 |
| 115 | HS7391ES |
Francis Ssali fssali@jcrc.org.ug
|
A5424 Menopausal Hormone Therapy for Women Living with HIV (HoT) | 2026-04-24 | 22 | $ 300,000 |
| 116 | HS7883ES |
FREDDIE SSENGOOBA sengooba@musph.ac.ug
|
Understanding and Strengthening Systems of Evidence to Improve Health Policy in Africa: A Comparative Multi-Country Study | 2026-06-11 | 45 | $ 299,258 |
| 117 | HS6274ES |
Ezekiel Mupere mupezik@gmail.com
|
Reducing short and long-term consequences of early stunted growth (MAGNUS-2). | 2025-09-03 | 45 | $ 296,218 |
| 118 | HS7522ES |
Nixon Niyonzima nixon.niyonzima@uci.or.ug
|
Clinical Effectiveness of Point-of-Care Breast Cancer Diagnostics in Ugandan Community Health Centers | 2026-05-14 | 22 | $ 288,866 |
| 119 | HS7676ES |
Eugene Ruzagira Eugene.Ruzagira@mrcuganda.org
|
Extended monitoring of HIV status and vaccine-induced seropositivity among PrEPVacc trial participants (PrEPVacc Extension Study). | 2026-06-01 | 12 | $ 288,865 |
| 120 | HS7026ES |
Suzanne Kiwanuka ksuxane@yahoo.com
|
Strategic Analytics for a Sustainable and Resilient Health Supply Chain in Uganda: An assessment of the financing landscape, fiscal space, interventions, subnational and last mile supply chain system performance | 2026-01-30 | 23 | $ 286,782 |
| 121 | HS6625ES |
ALEX KAYONGO alexkayongo@gmail.com
|
Clonotyping Airway T-cells to Uncover Microbiome-Specific Inflammotypes in HIV-Associated COPD | 2025-10-29 | 23 | $ 284,500 |
| 122 | SS4196ES |
Slyvia Aarakit saarakit@mubs.ac.ug
|
GREEN ENERGY FOR WOMEN AND YOUTH RESILIENCE IN UGANDA: BRIDGING THE SKILLS GAP THROUGH TECHNICAL AND VOCATIONAL EDUCATION AND TRAINING-TVET | 2025-09-03 | 28 | $ 280,038 |
| 123 | A637ES |
MARGARET AANYU maggieaanyu@gmail.com
|
Adopting multidisciplinary approaches in genetic improvements, nutritional enhancements and climate change adaptation for improved production of Nile tilapia in Uganda | 2025-09-09 | 36 | $ 279,206 |
| 124 | SS5152ES |
Michael King KINGM4@tcd.ie
|
Gender Focused Multi-Faceted Anti-Poverty Programs: Low-Cost Options for Scale-up | 2026-05-21 | 29 | $ 277,438 |
| 125 | HS6886ES |
John Bosco Ddamulira jddamulira@musph.ac.ug
|
Analysis of the current state of HIV-related stigma and discrimination in Uganda: A cross-sectional survey of the magnitude, drivers and facilitators, and effect on HIV prevention and care services. | 2026-01-30 | 51 | $ 268,547 |
| 126 | SS5147ES |
Milton Ayoki miltonayoki@gmail.com
|
From job displacement to economic resilience: Mapping the net impact of AI on formal and informal employment across three African economies | 2026-04-20 | 6 | $ 262,357 |
| 127 | A621ES |
Denis Mpairwe denis.mpairwe@mak.ac.ug
|
Building inclusive knowledge sharing hubs (Livestock Caf�s) for resilient pastoral livelihoods and rangeland restoration in East African drylands (Include2Restore) | 2025-09-26 | 81 | $ 258,634 |
| 128 | SS4724ES |
Konrad Burchard Burchardi konrad.burchardi@iies.su.se
|
Empowering Agriculturalists through Structured Experimentation (EASE) | 2026-02-05 | 17 | $ 258,000 |
| 129 | HS6310ES |
JOSELYN RWEBEMBERA joselynr36@gmail.com
|
Determining the Risk of Rheumatic Heart Disease Following Prophylaxis Discontinuation (GOAL-Keep) | 2025-08-18 | 28 | $ 255,900 |
| 130 | HS6912ES |
Emmanuel Kiiza Mwesiga emwesiga@chs.mak.ac.ug
|
Leveraging Digitization, Archiving and Artificial Intelligence Applications to Utilize Patient Charts for Research: A Pilot Study Examining Predictors of Sustained Mental Health Care Engagement in Ugandan Psychosis Patients | 2026-04-29 | 61 | $ 253,698 |
| 131 | HS7321ES |
GRACE KANSIIME graekan@gmail.com
|
REDUCING TB MORTALITY DURING AND AFTER TREATMENT THROUGH SCREENING FOR KIDNEY DYSFUNCTION AND IMPLEMENTATION OF A MORTALITY RISK PREDICTION SCORE IN UGANDA | 2026-04-10 | 23 | $ 253,000 |
| 132 | HS6241ES |
Bernard Kikaire kikaire@gmail.com
|
SEROPREVALENCE OF MARBURG VIRUS INFECTION AND OTHER WHO-PRIORITY PATHOGEN IN THREE (3) COUNTRIES IN AFRICA | 2025-07-04 | 11 | $ 250,000 |
| Totals across 132 studies | $ 871,058,901 | |||||